Publications

5674 Results

Clinical Trial in Progress: Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716)

Authors
S Hu-Lieskovan;J Moon;A Lau Clark;K Grossmann;J Sosman;D Campos;M Wu;C Ryan;A Ribas
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS9603); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
Year
2018
Research Committee(s)
Melanoma
Study Number(s)
S1607

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613

Authors
K Raghav;S McDonough;B Tan;CS Denlinger;A Magliocco;N Choong;N Sommer;F Scappaticci;D Campos;K Guthrie;ES Kopetz;M Fakih;H Hochster
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS3620)ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
S1613

Clinical Trial in Progress: Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)

Authors
A VanderWalde;M Latkovic-Taber;S Hu-Llieskovan;K Grossmann;J Sosman;D Campos;M Wu;A Ribas
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS9597); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Melanoma
Study Number(s)
S1616

Case-only analyses for identifying genotypes that modify the effect of finasteride in the Prostate Cancer Prevention Trial (PCPT): SWOG S9217

Authors
JY Dai;M Leblanc;P Goodman;MS Lucia;I Thompson;C Tangen
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 1551); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
Year
2018
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Nut consumption and survival in patients with stage III colon cancer: results from CALGB 89803 (Alliance)

Authors
T Fadelu;S Zhang;D Niedzwiecki;X Ye;L Saltz;R Mayer;R Mowat;R Whittom;A Hantel;A Benson;D Atienza;M Messino;H Kindler;A Venook;S Ogino;K Ng;K Wu;W Willett;E Giovannucci;J Meyerhardt;Y Bao;C Fuchs
Journal / Conference
Journal of Clinical Oncology Apr 10;36(11):1112-1120; Feb 28 [Epub ahead of print]
Year
2018
Research Committee(s)
Gastrointestinal
PMID
PMID29489429
PMC
PMC5891130
Study Number(s)
C89803

Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials

Authors
J Unger;A Moseley;B Symington;M Chavez-MacGregor;S Ramsey;D Hershman
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 6569); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Cancer Care Delivery

Patient Comorbid Conditions and Cancer Clinical Trial Participation

Authors
J Unger;D Hershman;M Fleury;R Vaidya
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 6540); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Cancer Care Delivery

Causal modeling of CALGB 80405 identifies network drivers of metastatic colorectal cancer (CRC)

Authors
F Innocenti;H-J Lenz;J Meyerhardt;D Niedzwiecki;A Nixon;E O'Reilly;F-S Ou;A Venook;RK Das;L Furchtgott;D Cunha;K Rich;J Latourelle;D Wuest;B Hayete;I Khalil
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 3570); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A Randomized Phase II Study of Anti-Pd1 Antibody [Mk-3475 (Pembrolizumab)] Alone Versus Anti-Pd1 Antibody plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Authors
J Luke;S Chmura;J Salama;H Al-Hallaq;C Hsu;S Yom;M Kozloff;J Allred;P Munster;G Schwartz
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr TPS9599); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster
Year
2018
Research Committee(s)
Melanoma
Study Number(s)
CTSU/A091605

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)

Authors
G Abou-Alfa;Q Shi;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;R Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;RK Kelley;A Siegel;T Zemla;I El Dika;A Venook;M Bertagnolli;J Meyerhardt;EM O'Reilly
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr e16107);ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), publication only
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80802